-
Evotec and Galapagos collaborate for new fibrosis target
pharmaceutical-technology
February 20, 2019
German biotechnology company Evotec has entered into a collaboration agreement with Belgo-Dutch pharmaceutical firm Galapagos for a new, undisclosed target to treat fibrosis....
-
AIT Therapeutics to Present High-Dose Nitric Oxide In Vitro Data at the North American Cystic Fibrosis Conference
biospectrumasia
October 17, 2018
Press Release AIT Cystic Fibrosis Pulmonary/Respiratory Medicine Clinical Research (R&D) Medical Affairs NACFC
-
Vivus, diving into the cystic fibrosis sphere, backs stadium step-climbing fundraiser
fiercepharma
September 29, 2018
With Pancreaze, a drug for cystic fibrosis patients, Vivus is stepping into an unfamiliar market. So earlier this month, it sponsored a fundraising event to get its name out.
-
Corbus nets over 600 endocannabinoid-related compounds, planning to develop 1-2 per year
fiercebiotech
September 21, 2018
The deal includes $250,000 upfront, plus up to $18.4 million in milestone payments for each compound Corbus develops.
-
Bristol-Myers Squibb and Nordic Bioscience Announce Collaboration for Fibrosis Biomarker Technology
americanpharmaceuticalreview
April 20, 2017
Bristol-Myers Squibb Company and Nordic Bioscience have announced a collaboration agreement to develop biomarker technology to potentially aid in the diagnosis and monitoring of fibrotic diseases including Non-alcoholic steatohepatitis (NASH).
-
AbbVie’s VIEKIRAX + EXVIERA receives positive opinion for eight-week treatment of GT1b HCV
pharmaceutical-technology
March 01, 2017
AbbVie has received a positive opinion for a shorter, eight-week treatment of VIEKIRAX (ombitasvir / paritaprevir / ritonavir tablets) + EXVIERA (dasabuvir tablets).
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
